CBS 2019
CBSMD教育中心
English

双重抗血小板治疗持续时间

科研文章

荐读文献

A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial Ticagrelor With or Without Aspirin After Complex PCI Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation

Clinical Trial2013 Dec 18;310(23):2510-22.

JOURNAL:JAMA. Article Link

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial

Feres F, Costa RA, OPTIMIZE Trial Investigators. Keywords: DAPT duration; Dual antiplatelet therapy (DAPT); DES; bleeding; coronary stenting

FULL TEXT PDF